Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model

  title={Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model},
  author={Irving Donadon and Mirko Pinotti and Katarzyna Rajkowska and Giulia Pianigiani and Elena Barbon and Elisabetta Morini and Helena Motaln and Boris Rogelj and Federico Mingozzi and Susan A. Slaugenhaupt and Franco Pagani},
  journal={Human Molecular Genetics},
  pages={2466 - 2476}
Abstract Familial dysautonomia (FD) is a rare genetic disease with no treatment, caused by an intronic point mutation (c.2204+6T>C) that negatively affects the definition of exon 20 in the elongator complex protein 1 gene (ELP1 also known as IKBKAP). This substitution modifies the 5′ splice site and, in combination with regulatory splicing factors, induces different levels of exon 20 skipping, in various tissues. Here, we evaluated the therapeutic potential of a novel class of U1 snRNA… 

Figures from this paper

A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I
RNA sequencing revealed the negligible impact of the U1F on the splicing profile and overall gene expression, thus pointing toward gene specificity, and provided early in vivo proof-of-principle of the correction potential of compensatory U1snRNAs in HTI.
Rescue of common exon‐skipping mutations in cystic fibrosis with modified U1 snRNAs
Results provide a common strategy based on modified U1 snRNAs to correct exon skipping in a group of disease‐causing CFTR mutations.
Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy
It is proved that U1snRNA-mediated splicing correction fully restores CDKL5 protein synthesis, subcellular distribution and kinase activity and provided insights on the morphological rescue of CDKl5 null neurons, reporting the first proof-of-concept of the therapeutic value of U1 SnRNAs acting on pre-mRNA splicing.
Disease‐causing variants of the conserved +2T of 5′ splice sites can be rescued by engineered U1snRNAs
expression of splicing‐competent cDNA constructs indicated that the splicing rescue produces an appreciable increase of secreted FIX protein levels, providing the first experimental evidence that even part of variants at the conserved 5′ss +2T nucleotide can be rescued, thus expanding the applicability of this U1snRNA‐based approach.
Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA
Viral delivery of a modified U1snRNP particle may be a novel therapeutic option against SMA, and RNA-seq analysis revealed potential drug rescues aberrant SMA expression and splicing profiles, which are mostly related to DNA damage, cell-cycle control and acute phase response.
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A
Data demonstrate that a single ExSpeU1 can efficiently rescue different mutations in the F8 exon 5 of coagulation factor (F)VIII gene (F8), and provide the first evidence of the applicability of the U1snRNA-based approach to Haemophilia A.
A novel role of U1 snRNP: Splice site selection from a distance.
  • R. SinghN. Singh
  • Biology
    Biochimica et biophysica acta. Gene regulatory mechanisms
  • 2019
ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia.


An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants
This is the first proof-of-concept in vivo that a unique ExSpeU1 can efficiently rescue gene expression impaired by distinct exon-skipping variants, which extends the applicability of ExSpe U1s to panels of mutations and thus cohort of patients.
An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects
ExSpeU1s are proposed as a novel therapeutic strategy to correct, in several human disorders, different types of splicing mutations associated with defective exon definition through splicing-competent cDNA constructs.
RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia.
The results show that tissue-specific expression of RBM24 can explain the neuron-specific aberrant splicing of IKBKAP exon 20 in familial dysautonomia, and that ectopic expression ofRBM24 in neuronal tissue could be a novel therapeutic target of the disease.
Improvement of SMN2 Pre-mRNA Processing Mediated by Exon-Specific U1 Small Nuclear RNA
Exon‐Specific U1s Correct SPINK5 Exon 11 Skipping Caused by a Synonymous Substitution that Affects a Bifunctional Splicing Regulatory Element
ExSpe U1 lentiviral‐mediated transduction of primary NS keratinocytes from a patient bearing the mutation recovered the correct full‐length SPINK5 mRNA and the corresponding functional lympho‐epithelial Kazal‐type related inhibitor protein in a dose‐dependent manner.
Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia.
It is found that relative WT:MU IKBKAP RNA levels were highest in cultured patient lymphoblasts and lowest in postmortem central and peripheral nervous tissues, suggesting that the relative inefficiency of WT I KBKAP mRNA production from the mutant alleles in the nervous system underlies the selective degeneration of sensory and autonomic neurons in FD.
Cardiac glycosides correct aberrant splicing of IKBKAP‐encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3
This study represents the first demonstration that digoxin possesses splice‐altering capabilities that are capable of reversing the impact of the FD‐causing mutation and demonstrates the ability of digoxin to impact the splicing process in neuronal cells, a cell type profoundly impacted by FD.
Kinetin Improves IKBKAP mRNA Splicing in Patients With Familial Dysautonomia
Not only did kinetin produce the desired effect on splicing in FD patients but also that effect seems to improve with time despite lack of dose change, the first report of a drug that produces in vivo mRNA splicing changes in individuals with FD.
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency.
Findings suggest compensatory U1-snRNAs as therapeutic tools in coagulation factor deficiencies caused by mutations at 5'ss, a frequent cause of severe defects.